BIOGRAPHICAL SKETCH
NAME
POSITION TITLE
Schentag, Jerome J.
Professor of Pharmaceutical Sciences and
Pharmacy, University at Buffalo. Founder and CEO,
TheraSyn companies
INSTITUTION AND LOCATION
University of Nebraska at Omaha
Philadelphia College of Pharmacy & Science
DEGREE
(if applicable)
B.S. Pharm.
Pharm.D.
MM/YY
1973
1975
FIELD OF STUDY
Pharmacy
Clinical Pharmacy
Positions and Honors
1973-1975:
1975-1976:
1976-1978:
1976-1981:
1977-2000:
1977-1980:
1978-1979:
1979-1998:
1979-1981:
1981-1986:
1981-2000:
1982-1998:
1986-present:
1988-1989:
1988-1989:
1989-1993:
1989-1998:
1989-1993:
1996-1997:
1996-1999:
1993-2003:
2000-present:
2002-present:
2007-present:
2007-present:
2012-present:
Staff Pharmacist, Thomas Jefferson University Hospital, Philadelphia PA
Postdoctoral Fellow in Clinical Pharmacokinetics, Department of Pharmaceutics, State University
of New York (SUNY) at Buffalo, School of Pharmacy (with Dr. W.J. Jusko)
Clinical Assistant Professor of Pharmaceutics, SUNY at Buffalo School of Pharmacy
Assistant Director, Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo NY
Consultant Staff, Millard Fillmore Hospital
Member Pharmacy and Therapeutics Committee, Millard Fillmore Hospital
Acting Director, The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital
Pharm.D. Admissions Cmttee, UB School of Pharmacy Member (1979-1984), Chair (1984-1998)
Assistant Professor of Pharmacy and Pharmaceutics, SUNY School of Pharmacy
Associate Professor of Pharmaceutics and Pharmacy, SUNY School of Pharmacy
Director, The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital
Member, Antibiotic Review Committee, Millard Fillmore Hospital
Professor of Pharmaceutical Sciences and Pharmacy, SUNY School of Pharmacy
Chairman, Recruitment Committee for Department of Pharmacy Chair
Member, Recruitment Committee, Department of Pharmacology Chair
SUNY School of Medicine
Director, Center for Clinical Pharmacy Research, SUNY at Buffalo School of Pharmacy
Director, Doctor of Pharmacy Program, SUNY at Buffalo School of Pharmacy
Member, Executive Committee, SUNY at Buffalo School of Pharmacy
Member, Pharmacy Dean Search Committee, SUNY at Buffalo
Member UB Incubator Evaluation Committee SUNY at Buffalo
Founder and CEO, Gastrotarget Corp, later became Smart Pill Corp. Marketed Smart Pill 2007
Founder and CEO, CPL Associates LLC
Founder and CEO, TheraSyn Pharmaceuticals, Inc
Founder and CEO, TheraSyn Sensors, Inc
Founder and CEO, TheraSyn DM, LLC. Now VP of R&D and Board Chairman
Founder and Chairman, MetaBrake LLC
1
Professional Societies: ACCP, ASPET, AphA, ASHP, AACP, ASM, NY Academy of Sciences, IDSA, ISAP,
SIDP
Editorial Boards: Pharmacotherapy, Ann of Pharmacotherapy, Antimicrobial Agents and Chemotherapy,
Pharmaceutical Research, Clin Pharmacology and Therapeutics, Clinical Pharmacokinetics
Other Professional Distinctions:
1985-1988:
Member, Sci Adv. Board, Healthcare Instruments and Devices Institute (HIDI), SUNY at Buffalo
1985:
Fellow, American College of Clinical Pharmacy
1980-1990:
Certificate of Qualification - Toxicology Laboratory Director, New York State Dept. of Health
1988-present: Fellow, Center for Entrepreneurial Leadership, SUNY at Buffalo School of Management
1989:
Distinguished Young Alumnus, Philadelphia College of Pharmacy and Science
1989:
ASHP Award for Sustained Contributions to the Literature of Hospital Pharmacy
1991:
ACCP Russell R. Miller Award
1991:
AAPS Research Achievement Award in Clinical Sciences
1994:
U.S. Patent #5,279,607 Site Specific Drug Delivery in the GI Tract
1995:
U.S. Patent #5,395,366 Noninvasive Fluid Sampling in the GI Tract
1995:
APhA Stimulation of Research Award
2006:
US Patent #7,326,387 Air Decontamination Devices
2009:
Visionary Inventor University at Buffalo (3 patent filings including Vaginal Pill, GI Smarter Pill
and Glucose Monitoring Methods and Devices)
2010:
UB Entrepreneur Award
Selected Peer-reviewed Publications (Selected from over 350 peer-reviewed publications)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Schentag JJ. Grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis - A
question of speed in bacterial killing. Canadian Journal of Infectious Disease. 1998;9(suppl E):16-22.
Schentag JJ. Antibiotic dosing--does one size fit all? Jama. 1998;279(2):159-60.
Schentag JJ. Pharmacokinetic and pharmacodynamic surrogate markers: studies with
fluoroquinolones in patients. Am J Health Syst Pharm. 1999;56(22 Suppl 3):S21-4.
Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to
improve efficacy and avoid resistance. J Chemother. 1999;11(6):426-39.
Schentag JJ. Antimicrobial management strategies for Gram-positive bacterial resistance in the
intensive care unit. Crit Care Med. 2001;29(4 Suppl):N100-7.
Schentag JJ. Pharmacology of Hospital-Based Acid Suppression. Am J Health-Sys Pharmacy. 2002(In
Press).
Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and
pharmacodynamic theories? Clin Infect Dis. 2001;32 Suppl 1:S39-46.
Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir
carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol. 2007;47(6):689-96.
Schentag JJ, Klugman KP, Yu VL, et al. Streptococcus pneumoniae bacteraemia: pharmacodynamic
correlations with outcome and macrolide resistance-a controlled study. Int J Antimicrob Agents.
2007;30(3):264-9.
Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial
killing rates. Part 2: human trials. Ann Pharmacother. 2003;37(10):1478-88.
Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial
killing rates. Part 1: In vitro and animal models. Ann Pharmacother. 2003;37(9):1287-98.
Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with
the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents
Chemother. 1998;42(3):521-7.
2
13.
14.
15.
16.
17.
18.
19.
20.
Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and
pharmacodynamics of oral grepafloxacin in patients with AECB. J Antimicrob Chemother. 1997;40
Suppl A:45-57.
Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of
intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37(5):1073-81.
Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as
treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or
who have failed to respond to, vancomycin. J Antimicrob Chemother. 2002;50(6):1017-26.
Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its
relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.
Antimicrob Agents Chemother. 2007;51(7):2582-6.
Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC, Jr.
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is
predictive of failure of vancomycin therapy. Clin Infect Dis. 2004;38(12):1700-5.
Kiem S, Schentag JJ. Impact of organism species on microbial eradication and development of
resistance in severe gram-negative pneumonia. J Chemother. 2010;22(2):103-9.
Monte SV, Schentag JJ, Adelman MH, Paladino JA. Characterization of cardiovascular outcomes in
a type 2 diabetes glucose supply and insulin demand model. J Diabetes Sci Technol. 2010;4(2):382-90.
Monte SV, Schentag JJ, Adelman MH, Paladino JA. Glucose supply and insulin demand dynamics
of antidiabetic agents. J Diabetes Sci Technol. 2010;4(2):365-81.
Additional recent publications of importance to the field (Most recent first)
1.
2.
3.
4.
5.
6.
7.
8.
9.
Tan LT, Holthoff WG, Steves JM, Bright FV. Probe-dependent microenvironments within
biodegradable films formed from poly(l-lactic acid) and pluronic 104. Appl Spectrosc. 2010;64(4):35964.
Holthoff EL, Bright FV. Photophysics associated with site selectively templated and tagged xerogel
sensor platforms. Appl Spectrosc. 2010;64(7):714-9.
Bright FV, Holthoff EL. Dynamics within site selectively templated and tagged xerogel sensor
platforms. Appl Spectrosc. 2010;64(10):1073-7.
Andolina CM, Holthoff WG, Page PM, Mathews RA, Morrow JR, Bright FV. Spectroscopic system
for direct lanthanide photoluminescence spectroscopy with nanomolar detection limits. Appl Spectrosc.
2009;63(5):483-93.
Holthoff EL, Bright FV. Photophysics of 9,10-anthracenediol and a bifunctional sacrificial template in
solution and xerogels. Appl Spectrosc. 2008;62(4):345-52.
Tehan EC, Higbee DJ, Wood TD, Bright FV. Tailored quartz pins for high-density microsensor array
fabrication. Anal Chem. 2007;79(14):5429-34.
Holthoff EL, Bright FV. Molecularly templated materials in chemical sensing. Anal Chim Acta.
2007;594(2):147-61.
Tao Z, Tehan EC, Tang Y, Bright FV. Stable sensors with tunable sensitivities based on class II
xerogels. Anal Chem. 2006;78(6):1939-45.
Tao Z, Tehan EC, Bukowski RM, Tang Y, Shughart EL, Holthoff WG, Bright FV, et al. Templated
xerogels as platforms for biomolecule-less biomolecule sensors. Anal Chim Acta. 2006;564(1):59-65.
Research Support
Ongoing Research Support
CPL Associates LLC is a Contract Research organization currently working on Drug development Clinical
Trials in Sepsis, Pneumonia, and Diabetes. All clinical trials involve close collaboration with Physicians, and
3
the CPL team includes Specialists in PK/PD and other disciplines of Pharmacometrics. These skills are
applied to Clinical trials as well as Data analysis and modeling.
Role: PI or Co-Investigator on all Grants
Center for Protein Therapeutics, University at Buffalo. Two active grants (2009-2010) supporting the
development of Sensors for use in PK studies in Animal models and sensors for real-time assay of Glucose,
Insulin and GLP-1.
Role: PI
Center for Advanced Technology Program, University at Buffalo. Two active Grants provide matching funds
for sensor development and application to Diabetes treatment and drug development. Matching funds are
provided by NY State and by Private Companies.
4